-
Supplement product lines and extend sales market... Since August, multiple pharmaceutical companies have launched mergers and acquisitions
Time of Update: 2022-08-20
According to the announcement, Sino-US Huadong will invest a total of no more than 396 million yuan to obtain a 60% stake in Huaren Technology and become its controlling shareholder by means of capital increase and transfer of shares .
-
Two pharmaceutical companies announced acquisitions within 1 day, in order to expand their business scope and solve environmental problems
Time of Update: 2022-08-20
0659 million yuan Lukang Pharmaceutical: It plans to purchase 60% equity of Zhonghe Environmental Protection Company held by Hualu Group for 62.
0659 million yuan Lukang Pharmaceutical: It plans to purchase 60% equity of Zhonghe Environmental Protection Company held by Hualu Group for 62.
-
The brand of Dongcheng Pharmaceutical has been renewed and entered a new era of take-off and development
Time of Update: 2022-08-20
Dongcheng Orange/Stable Gray new image upgrade concept After more than 20 years of development, as a heparin expert and nuclear drug pioneer, Dongcheng Pharmaceutical's API business and nuclear drug business occupy an important position in the market .
-
Guangdong issues guidelines for the development of forest, grass and Chinese medicinal materials industry
Time of Update: 2022-08-20
The "Guidelines for the Development of Forest, Grass and Chinese Medicinal Materials Industry in Guangdong Province" proposes that Guangdong should take regional climate, soil and geographical environment conditions as the basic elements, take the distribution of forest land resources and community characteristics as important conditions, and take regional socio-economic levels and historically formed conditions.
-
In order to open up new markets, pharmaceutical machine companies are continuously increasing investment in innovative research and development
Time of Update: 2022-08-20
While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing (Source: Pharmaceutical Network) While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing On August 10, the 2022 semi-annual report released by Huadong Medicine showed that the company achieved operating income of 18.
-
There is a reduction and an increase in holdings. Is CRO still worth looking forward to?
Time of Update: 2022-08-20
In addition, the performance of Haite Bio, Zhaoyan New Drug, WuXi AppTec, and Kyushu Pharmaceuticals are also expected to achieve growth, with an increase of more than 20% in the first half of the year .
-
Menarini Group's drug elastrant has been granted priority review status by the FDA
Time of Update: 2022-08-20
About the Phase 3 study of elasitran (RAD1901) and EMERALD Elastrant is an investigational selective estrogen receptor degrader (SERD) currently being evaluated as a once-daily oral treatment for patients with ER+/HER2- advanced or metastatic breast cancer .
-
Pharmaceutical companies are actively exploring the children's drug market, and some companies have raised nearly 297 million yuan
Time of Update: 2022-08-20
For example, Kangzhi Pharmaceutical recently announced that the company plans to raise no more than 297 million yuan, and the net amount of funds raised after deducting issuance expenses is planned to be used for children's drug research and development projects .
-
Is financing in the domestic medical and health sector still "hot"?
Time of Update: 2022-08-20
In recent years, the rapid development of stem cell therapy in China, and continuous breakthroughs under the continuous advancement of technology, has accelerated the pace of clinical application in many fields such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, cardiovascular and cerebrovascular diseases, and has broad market prospects.
-
The highest drop is 96.67%!
Time of Update: 2022-08-20
62%; duloxetine hydrochloride enteric-coated capsules (30mg calculated by C18H19NOS) decreased from 171 yuan / bottle dropped to 21.
62%; duloxetine hydrochloride enteric-coated capsules (30mg calculated by C18H19NOS) decreased from 171 yuan / bottle dropped to 21.
-
Many large tertiary hospitals purchase "do not accept imported products"!
Time of Update: 2022-08-19
Consumables have made imported products experience a huge impact on price:In addition to the centralized procurement of medical device consumables, the original research formed by the centralized procurement of national drugs with a large amount of drugs is gradually included in the scope of centralized procurement of drugs with "large clinical dosage and high procurement amount", covering all kinds of drugs that are clinically necessary and of reliable quality and are marketed in China.
-
The ADC drug market is surging, and the innovation battle will be unveiled!
Time of Update: 2022-08-19
As of July this year, Kelun Pharmaceutical and CSPC announced within 3 days that two ADC drugs (ie antibody-drug conjugates) were authorized to Merck and an American biopharmaceutical company respectively, with a total transaction value of more than 2 billion US dollars .
-
Overseas institutions researched more than 60 listed companies, focusing on electronics, power equipment, medicine and biology and other industries
Time of Update: 2022-08-19
In the past 10 days, a total of 7 listed pharmaceutical and biological companies have received the attention of overseas institutions, including Jiudian Pharmaceutical, Changchun High-tech, Walter Dyne, Weiss Medical, Weili Medical, etc.
-
Multinational pharmaceutical companies accelerate their deployment in China, and another new drug is approved for clinical use
Time of Update: 2022-08-19
[Pharmaceutical Network Industry News] On August 16, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of the People's Republic of China showed that Merck's Class 1 new drug MK-4830 injection has obtained an implied license for clinical trials and is intended to be developed for use in Treatment of advanced solid tumors .
-
Several vaccination centres in Hong Kong increase vaccination services for young children
Time of Update: 2022-08-19
Children's Hospital Yang Hebei Yin said after inspecting the two vaccination centers that only vaccination against the new crown can reduce the risk of severe illness, death or serious sequelae after infection.
-
Notice on holding a training course on research and exchange of key quality attributes of pharmaceutical excipients
Time of Update: 2022-08-19
All relevant units: With the deepening of the related review of pharmaceutical excipients and preparations, the focus on key quality attributes of pharmaceutical excipients in the entire life cycle o
-
In order to enter the medical insurance, this drug with an annual cost of more than 1 million yuan is reduced to less than 500,000 yuan!
Time of Update: 2022-08-19
On August 8, Heilongjiang Province announced the list of drugs that companies applied for price reduction in July, including ripatinib, which has an annual cost of over one million yuan .
-
The enthusiasm for the research and development of new Chinese medicines is high, and many pharmaceutical companies have submitted clinical applications since the second half of the year!
Time of Update: 2022-08-19
At the same time, the Blue Book pointed out that in recent years, the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for new Chinese medicine clinical trials and new drug marketing authorization applications has increased year by year .
-
The import of sagebrush has decreased, and the long-term will continue to be optimistic!
Time of Update: 2022-08-19
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
-
The leading pharmaceutical chain company with more than 10,000 stores has been surveyed by more than 50 institutions since the second half of the year!
Time of Update: 2022-08-19
On August 1, the People's Pharmacy released the minutes of the institutional investor exchange activity meeting (2022.
On August 1, the People's Pharmacy released the minutes of the institutional investor exchange activity meeting (2022.
